| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President and CEO
1 company
Purnanand D Sarma last filed a Form 4 in June 2023, as President and CEO at IMNM. Purnanand D Sarma's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 10,500 shares of IMNM. Net of sales, the IMNM filings show accumulation of 10,500 shares.
Purnanand D Sarma has 4 Form 4 filings on record from May 2021 to June 2023, all as President and CEO at Immunome (IMNM), 2021–2023.
The 4 reported transactions were 3 option or other derivative awards and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $193K and no sales.
The only open-market purchase was 10,500 shares of IMNM at an average $18.41 on May 25, 2021, about $193K. Twelve months later IMNM was down 84%.
Shares as reported in the last Form 4 for each company; the most recent is from June 2023. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 25, 2021 | IMNM Immunome Inc. | President and CEO | Buy | 10,500 | $18.41 | $193,305.00 | New | -24.2% | -83.8% |